scholarly article | Q13442814 |
P819 | ADS bibcode | 2014PLoSO...986543Z |
P356 | DOI | 10.1371/JOURNAL.PONE.0086543 |
P932 | PMC publication ID | 3897724 |
P698 | PubMed publication ID | 24466143 |
P5875 | ResearchGate publication ID | 259920372 |
P50 | author | Yunshi Zhong | Q114315420 |
P2093 | author name string | Qi Lin | |
Li Ren | |||
Jianmin Xu | |||
Dexiang Zhu | |||
Tianshu Liu | |||
Ye Wei | |||
Qinghai Ye | |||
Xinyu Qin | |||
Lechi Ye | |||
P2860 | cites work | Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). | Q53388486 |
Peri-operative chemotherapy for resectable colorectal liver metastasis: does timing of systemic therapy matter? | Q82418582 | ||
Resectable colorectal liver metastases: optimal sequencing of chemotherapy | Q83509575 | ||
Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? | Q84766645 | ||
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial | Q24647888 | ||
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. | Q33330997 | ||
Surgery for colorectal liver metastases. | Q33834452 | ||
Trends in long-term survival following liver resection for hepatic colorectal metastases | Q34523502 | ||
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases | Q36464103 | ||
Hepatectomy for resectable colorectal cancer metastases--indicators of prognosis, definition of resectability, techniques and outcomes | Q36867825 | ||
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy | Q37287048 | ||
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel | Q37372198 | ||
The role of preoperative chemotherapy in patients with resectable colorectal liver metastases | Q37530660 | ||
Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases | Q37621305 | ||
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver | Q37625605 | ||
Surgical management of hepatic metastases of colorectal origin | Q37630485 | ||
Systemic chemotherapy and its implications for resection of colorectal liver metastasis | Q37644758 | ||
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. | Q37718030 | ||
Role of adjuvant therapy after resection of colorectal cancer liver metastases | Q37724550 | ||
Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? | Q37768890 | ||
Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit? | Q37821841 | ||
The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? | Q37831218 | ||
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer | Q37907117 | ||
Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? | Q39754325 | ||
Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? | Q42841253 | ||
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. | Q44486167 | ||
Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. | Q45924115 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
neoadjuvant chemotherapy | Q108855558 | ||
P304 | page(s) | e86543 | |
P577 | publication date | 2014-01-21 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases | |
P478 | volume | 9 |
Q37735615 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer |
Q34207776 | Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? |
Q38836982 | Influence of neoadjuvant chemotherapy on resection of primary colorectal liver metastases: A propensity score analysis |
Q38256165 | Liver-directed therapies in metastatic colorectal cancer |
Q38386343 | Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers |
Q90581021 | Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases |
Q47769444 | Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial |
Q92727057 | Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases |
Q36344123 | Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases |
Q90627128 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) |
Q35988684 | The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis |
Q38528849 | Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go? |
Search more.